Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study

Buser, K.; Joss, R; Piquet, D.; Aapro, Matti; Cavalli, F.; Haefliger, J. M.; Jungi, W. F.; Bauer, Jean; Obrist, R.; Brunner, K. W.; Weber, Tom; Verity, L.; Butcher, M. E.

doi:10.1093/oxfordjournals.annonc.a058556

Cited by 26 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Oral ondansetron is usually employed to prevent acute emesis in moderately emetogenic regimens [8,9], In the present study, however, the association of oral ondanse tron and dexamethasone also seemed efficacious in cisplatin-based chemotherapy [16], The response rate was comparable to that obtained with various intravenous combinations containing ondansetron and dexametha sone [3,4], and higher than with intravenous dexametha sone alone [17]. These results need to be confirmed, of course, in double-arm randomized trials.…”

Section: Discussion and C Onclusionsmentioning

confidence: 49%

“…A single-dose schedule has proved as effective as multiple doses or continuous infusion [5]. The drug is not usually given orally in highly emetogenic chemotherapy [6,7], but has been successfully used in moderately eme togenic regimens [8,9] and for the prevention of delayed emesis; it seems less effective in the latter, however, and its role is controversial [2,[10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Ondansetron and Intravenous Dexamethasone in the Prevention of Cisplatin-lnduced Emesis

et al. 1995

View full text Add to dashboard Cite

Fifty-eight previously untreated patients with gynecological cancer, assigned to cisplatin-based chemotherapy (40–80 mg/m²), received the following antiemetic treatment: day 0, oral ondansetron 8 mg 3 times/day + intravenous dexamethasone 16 mg; days 1–7, oral ondansetron 8 mg twice/day. In cycle 1 complete or major control (0–2 emetic episodes) was achieved in 94.6% of the patients in the acute phase (day 0) and in 89.2% in the delayed phase (day 1-7). In the subgroup receiving cisplatin ≥ 75 mg/m² the effect on acute and delayed emesis decreased significantly with subsequent courses. Reversible side effects were observed in 8.9% of the cases. Oral ondansetron was efficacious, well tolerated and is worth testing further in randomized trials with intravenous therapy.

show abstract

Section: Discussion and C Onclusionsmentioning

confidence: 49%

Section: Introductionmentioning

confidence: 99%

Oral Ondansetron and Intravenous Dexamethasone in the Prevention of Cisplatin-lnduced Emesis

et al. 1995

View full text Add to dashboard Cite

show abstract

“…5-HT3 receptor blockade results in a significant reduction of cyclophosphamide-induced emesis [1,2,5,9,15,18]. However, the observation that a significant proportion of patients are only partially protected from cyclophosphamide-induced vomiting despite the use of 5-HT3 antagonists makes it probable that additional mechanisms are involved in the pathophysiology of emesis.…”

Section: Discussionmentioning

confidence: 99%

“…Emesis induced by combinations of cyclophosphamide and anthracycline is observed in 87%-97% of patients who have not received antiemetic prophylaxis [1,9,16]. Serotonin-3-receptor (5-HT3) antagonists have proven efficacy in the prophylaxis of cyclophosphamide-induced emesis in both clinical [1,2,5,9,15] and experimental settings [18]. The latter findings suggest that serotonin (5-HT) and 5-HT3 receptors are involved in the pathophysiology of cyclophosphamideinduced emesis.…”

Section: Introductionmentioning

confidence: 99%

5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone

Bois

Vach

Holy

et al. 1996

Support Care Cancer

View full text Add to dashboard Cite

The aim of the work was to evaluate the impact of cyclophosphamide and ondansetron on serotonin metabolism measured by urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion. The pattern of urinary 5-HIAA excretion was analysed within 24 h following cyclophosphamide, epirubicin and 5-fluorouracil (FEC) chemotherapy (n = 14), ondansetron as single agent (n = 31), and in a control group (n = 62). 5-HIAA was measured by a fluorescence/polarisation immunoassay. Both FEC and ondansetron alone induced a significantly higher 5-HIAA increase following the first 12 h after drug administration when compared to the control group. The comparison of quantitative variables of 5-HIAA excretion between FEC and ondansetron failed to reveal any statistical differences. Cyclophosphamide-based chemotherapy is associated with only minor increases of 5-HIAA excretion. Analysis of 5-HIAA excretion does not help in the description of the pathophysiology of cyclophosphamide-induced emesis. In contrast to experimental data, serotonin 3 receptor antagonism with ondansetron induces an increase of 5-HIAA excretion in humans.

show abstract

“…Buser et al [11] compared oral ondansetron (8 mg 3 times/day) with placebo in a randomized, double-blind, parallel-group study in 82 breast cancer patients. Sixtyfive percent of patients given placebo experienced emesis at some point during the 15-day treatment period com pared with 40% given ondansetron (p = 0.027).…”

Section: Kargermentioning

confidence: 99%

Optimal Control of Cyclophosphamide-lnduced Emesis

Stewart¹

1996

Oncology

View full text Add to dashboard Cite

Cyclophosphamide induces moderate to severe emesis. The severity of emesis is dependent on the dose of cyclophosphamide and on the addition of other cytotoxic drugs. A review of the literature dividing studies according to the dose of cyclophosphamide and the specific cytotoxic combination shows that ondansetron plus dexamethasone provides optimal antiemetic therapy in patients receiving standard or high-dose cyclophosphamide ( ≥450 mg/m²). These studies also show that it is important to give antiemetic therapy to cover the prolonged duration emesis and nausea induced by these regimens, e.g. intravenous CMF/(F)AC/(F)EC. For continuous ‘oral’ (low-dose) CMF chemotherapy, oral ondansetron or oral metoclopramide plus intravenous (or possibly oral) dexamethasone are effective antiemetic therapies.

show abstract

Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study

Cited by 26 publications

References 6 publications

Oral Ondansetron and Intravenous Dexamethasone in the Prevention of Cisplatin-lnduced Emesis

Oral Ondansetron and Intravenous Dexamethasone in the Prevention of Cisplatin-lnduced Emesis

5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone

Optimal Control of Cyclophosphamide-lnduced Emesis

Contact Info

Product

Resources

About